OQS
ARQT icon

Occudo Quantitative Strategies’s Arcutis Biotherapeutics ARQT Stock Holding History

Occudo Quantitative Strategies’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,979
Closed -$202K – 869
2021
Q1 		$202K Sell
6,979
-5,542
-44% -$173K 0.04% 617
2020
Q4 		$352K Buy
+12,521
New +$307K 0.11% 356

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Occudo Quantitative Strategies's ARQT Position: Q2 2021 in Review

Occudo Quantitative Strategies sold out of Arcutis Biotherapeutics (ARQT) in Q2 2021, closing a stake of 6,979 shares — an estimated $202K sold.

Occudo Quantitative Strategies first reported a position in ARQT in Q4 2020 and held it in 2 quarters. The position peaked at $352K in Q4 2020. 102 funds tracked by Wall St. Rank hold ARQT as of Q2 2021.

  • Occudo Quantitative Strategies reported no remaining Arcutis Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 6,979 Arcutis Biotherapeutics shares in Q2 2021, an estimated $202K.
  • Occudo Quantitative Strategies first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 2 quarters.
  • Occudo Quantitative Strategies's Arcutis Biotherapeutics position peaked at $352K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2021.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.